Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22795798 | 0.80 | NOS3 (0.32) | — | |
| SCHEMBL23642073 | 0.72 | ALDH1A1 (0.43) | KDM4ETP53 | |
| SCHEMBL18659476 | 0.71 | NOS3 (0.33) | — | |
| SCHEMBL19209829 | 0.66 | ALPL (0.31) | — | |
| SCHEMBL11723578 | 0.66 | — | — | |
| SCHEMBL23244659 | 0.65 | RPS6KB1 (0.36) | KDM4E | |
| SCHEMBL22509543 | 0.64 | CDK5 (0.34) | KDM4ETP53 | |
| SCHEMBL13733079 | 0.64 | RXFP1 (0.39) | KDM4E | |
| SCHEMBL14262407 | 0.64 | CYP19A1 (0.36) | KDM4ETP53 | |
| SCHEMBL15261418 | 0.63 | KDM4E (0.46) | KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | HNMT, EHMT2, SHMT2 | KDM4E 235/4885TP53 858/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | KDM4E 212/4885TP53 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.